$GILD News

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?

Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access

Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative

Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166

RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $120

Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156

Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155

Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector

Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?

Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Gilead Sciences Receives FDA Approval For Its Trodelvy Antibody-Dug Conjugate To Treat Adult Patients With Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Gilead Sciences: The Market Is Underestimating Its Growth Runway

Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?